Tests low-dose aspirin added to standard treatment for bipolar disorder
Tests low-dose aspirin added to usual care in adults with bipolar disorder.
Key facts
- Who runs it
- Instytut Psychiatrii I Neurologii
- Where
- Częstochowa, Swiecie, and Warsaw, PolandSee the 4 sites
- Registry title
- Study to evaluate the efficacy and safety of low-dose aspirin as an add-on to standard therapy in patients with bipolar disorder (ASPIRIN BD)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 19 May 2023
- Planned end
- 30 Apr 2026
- Type of study
- Interventional
- Record updated
- 9 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-60 with bipolar disorder who are in a depressive episode and already take a mood stabilizer. It tests low-dose aspirin added to usual treatment.
- Age
- 18-60 years
- Sex
- Women and men can join.
- Disease stage
- Bipolar disorder (ICD-10 code F31) with a current depressive episode (ICD-10 codes F31.3-F31.5).
- Earlier treatment
- Must currently take at least one mood stabilizer, but not a valproate. Valproates within 7 days before the start are not allowed.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Known allergy to aspirin or other NSAIDs, or regular use of aspirin for other diseases
- Regular use of steroids, anti-inflammatory drugs, blood thinners or certain other listed drugs
- Serious uncontrolled physical illness, such as stomach ulcer, liver or kidney disease, HIV or hepatitis
- Other severe mental disorders, or current non-drug treatments such as psychotherapy or electroconvulsive therapy
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Diagnosis of bipolar disorder (criterion verified by the qualifying physician on the basis of clinical history and criteria included in the classification of diseases ICD-10, code F31)
- Current episode of depression (ICD-10 codes F31.3-F31.5)
- Age 18-60 years; women and men
- Current treatment with at least one mood stabilizer recommended in bipolar disorder, except for valproates
- The patient is able to give informed consent to participate in the study
- The patient's body mass index is within the appropriate range (BMI> 18 and <40 kg / m2, where BMI = body weight (kg) / [height (m)] 2)
- In women of childbearing age, a negative serum pregnancy test at screening and agreement to use highly effective contraceptive methods during the study (Women of childbearing potential (WOCBP) is defined as any woman or adolescent who has begun menstruation. A postmenopausal woman is defined as a woman who is over the age of 45 and has not had a menstrual period for at least 12 months). *Due to enzyme induction, carbamazepine may cause hormonal contraception to be ineffective, so patients of childbearing age taking carbamazepine as standard therapy should be advised to use other effective methods of contraception
Who cannot take part
- Current use of non-pharmacological treatments (psychotherapy and biological treatments, i.e. electroconvulsive therapy, phototherapy, deep brain stimulation, transcranial magnetic stimulation)
- Taking valproates within 7 days prior to the start of the study (due to the risk of significant interactions with ASA)
- A patient who received any investigational drug not authorized in the country where the clinical trial is conducted within 30 days immediately before the start of the trial
- Coexisting severe mental disorders (schizophrenia, dementia, addiction, OCD, depression other than in the course of BD)
- Taking acetylsalicylic acid in a chronic manner due to somatic diseases
- Known allergy or hypersensitivity to ASA or other NSAIDs
- Regular use of steroid or non-steroidal anti-inflammatory drugs (occasional use of NSAIDs is allowed), methotrexate, digoxin, acetazolamide, antidiabetic drugs - insulin and drugs from the sulfonylurea group, anticoagulants (coumarin derivatives, heparin, oral anticoagulants from the group of non-vitamin K antagonists rivaroxaban, apixaban, dabigatran), thrombolytic or platelet aggregation drugs (ticlopidine, clopidogrel)
- Asthma, which, in the investigator's opinion, would increase the risk of an asthma attack; history of serious somatic disease (e.g. significant valvular heart disease, heart failure, hypertrophic cardiomyopathy, severe or worsening cardiomyopathy, clinically significant ECG abnormalities (defined as PR> 240msec, QRS complex> 110msec, QTcF> 500, ST segment depression) > 2 mm, ST-segment elevation> 1 mm, severe obstructive pulmonary disease, untreated thyroid disease, diagnosed HIV or hepatitis A, B or C, myocardial infarction in the last 6 months, insulin-dependent diabetes mellitus, gout). includes any somatic uncontrolled (in the last 3 months prior to study entry) disease states; a positive history of gastrointestinal, liver or kidney disease, or any other abnormal condition that impairs the function of these organs and may result in the possibility of altered absorption, excessive accumulation, or metabolic disorders or excretion of study medication. such as: history of major gastrointestinal surgery (e.g. gastrectomy, gastroenterostomy, bowel resection etc.) or a current diagnosis of an active gastrointestinal disease, gastric or duodenal ulceration, chronic gastrointestinal disease (e.g. ulcerative colitis, ileitis or gastrointestinal bleeding); liver damage, ie values ≥ 3 times the upper limit of normal for at least two of the following - ALT, ASP, LDH, alkaline phosphatase, or bilirubin; impaired renal function as indicated by clinically significant abnormalities for blood urea nitrogen (≥ 30 mg / dL) and creatinine (≥ 2 mg / dL), as well as by the presence of abnormal urine components (eg Albuminuria)
- Patients with menorrhagia. Objectively heavy menstrual bleeding is defined as prolonged (>7 days) excessive blood loss of more than 80 mL per menstrual cycle. Clinical signs predictive of heavy menstrual bleeding include clots >2.5 cm in size, low serum ferritin levels, seepage and the need to change a sanitary pad or tampon more often than every hour, as well as menstrual bleeding
- Pregnant or breastfeeding women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Poland
- Holimedyk Instytut Zdrowia Psychicznego Sp. J.Częstochowa, PolandTaking people
- Wojewodzki Szpital Dla Nerwowo I Psychicznie Chorych Im. Dr J. BednarzaSwiecie, PolandTaking people
- Instytut Psychiatrii I NeurologiiWarsaw, PolandTaking people
- Samodzielny Wojewodzki Zespol Publicznych Zakladow Psychiatrycznej Opieki Zdrowotnej W WarszawieWarsaw, PolandTaking people
About the trial
What the trial wants to find out
The main aim of the study is to assess the efficacy and safety of low-dose acetylsalicylic acid (150 mg / d) as an add-on treatment to standard therapy in the treatment of bipolar disorder.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of low-dose aspirin as an add-on to standard therapy in patients with bipolar disorder (ASPIRIN BD)
- Plain-language title
- Tests low-dose aspirin added to standard treatment for bipolar disorderGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-516584-86-00, who can take part
- Record updated
- 9 August 2024